FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OIVID APP	TOVAL					
OMB Number:	3235-0287					
Estimated average bu	ırden					
hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* LOSORDO DOUGLAS W (Last) (First) (Middle)						Issuer Name and Ticker or Trading Symbol Caladrius Biosciences, Inc. [CLBS] Date of Earliest Transaction (Month/Day/Year)									ck all applica Director	able) give title	g Person(s) to Issu 10% Ow Other (s below) Lemarks		vner	
C/O CALADRIUS BIOSCIENCES, INC.					01/25/2016									See Meilians						
106 ALL	EN ROAD																			
(Street) BASKIN RIDGE	IG N	J	07920		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Inc Line)	•				ا ا		
(City)	(S	state)	(Zip)																	
		Та	ble I - Nor	n-Deriv	ativ	/e S	ecurities	s Ac	quired,	Dis	posed o	of, or B	ene	ficially	Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						Execution if any	A. Deemed xecution Date, any Month/Day/Year)		3. Transaction Code (Instr.) 8) 4. Securi Disposed					Beneficia Owned Fe	s lly ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A)	or	Price	Reported Transacti (Instr. 3 a	ion(s)			(Instr. 4)	
Common Stock 03				01/25	25/2016				A		76,000)(1)	A	\$0	134,867(2)			D		
Common Stock 01.				01/25	25/2016				F		8,03	2	D	\$0.63	126,835(2)			D		
			Table II -								osed of				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	ransaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date E Expiratio (Month/D	n Date	•	of Secu Underly Derivati	7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported	e C S Illy C C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Co	ode	v	(A)	(D)	Date Exercisal		Expiration Date	Title	or Nu	mount umber Shares		Transaction(s) (Instr. 4)				
Options to Purchase Common Stock	\$0.63	01/25/2016		1	A		125,000		(3)		01/25/2026	Commo Stock	n 12	25,000	\$0	125,0	00	D		

Explanation of Responses:

- 1. Represents 76,000 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan. 25% of the shares of restricted stock vest immediately on the grant date and the remaining 75% of the shares of restricted stock will vest quarterly over the following 12 quarters.
- 2. Includes 57,000 shares of unvested restricted stock.
- 3. 25% of the shares underlying the Options vest immediately on the grant date and the remaining 75% of the shares underlying the Options will vest quarterly over the following 12 quarters.

Remarks:

Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer

Douglas W. Losordo, By: /s/
Todd C. Girolamo, Esq., 01/27/2016
Attorney-in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.